Tempest Therapeutics Inc
For the period ended Jun 13, 2024. Filed Apr 23, 2024.
View on SEC.govAbout this filing
What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.
Jun 13, 2024 · Filed Apr 23, 2024
Use the contents to explore the available documents and sections.
Contents
Table of Contents
| QUESTIONS AND ANSWERS ABOUT THESE PROXY MATERIALS AND VOTING | 1 |
|---|---|
| PROPOSAL 1 ELECTION OF DIRECTORS | 7 |
| INFORMATION REGARDING DIRECTOR NOMINEES AND CONTINUING DIRECTORS | 8 |
| INFORMATION REGARDING THE BOARD OF DIRECTORS AND CORPORATE GOVERNANCE | 10 |
| PROPOSAL 2 ADVISORY VOTE ON NAMED EXECUTIVE OFFICER COMPENSATION | 18 |
| PROPOSAL 3 RATIFICATION OF SELECTION OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM | 19 |
| EXECUTIVE OFFICERS | 21 |
| EXECUTIVE AND DIRECTOR COMPENSATION | 22 |
| EQUITY COMPENSATION PLAN INFORMATION | 33 |
| SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT | 34 |
| TRANSACTIONS WITH RELATED PERSONS AND INDEMNIFICATION | 36 |
| OTHER INFORMATION FOR STOCKHOLDERS | 37 |
| OTHER MATTERS | 38 |
Website References
You may also access additional information about Tempest Therapeutics, Inc. atwww.tempesttx.com andir.tempesttx.com. References to our websites throughout this proxy statement are provided for convenience only and the content on our website does not constitute a part of this proxy statement.
PROXY STATEMENT
FOR THE 2024 ANNUAL MEETING OF STOCKHOLDERS
TO BE HELD ON JUNE 13, 2024
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.